Last update 09 May 2025

Tofogliflozin Hydrate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Tofogliflozin, Tofogliflozin (USAN), Tofogliflozin anhydrous
+ [11]
Target
Action
inhibitors
Mechanism
SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Japan (24 Mar 2014),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC22H28O7
InChIKeyZXOCGDDVNPDRIW-NHFZGCSJSA-N
CAS Registry1201913-82-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2
Japan
24 Mar 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Fibrosis, LiverPhase 2
United States
14 Nov 2022
Fibrosis, LiverPhase 2
Japan
14 Nov 2022
Fibrosis, LiverPhase 2
Argentina
14 Nov 2022
Fibrosis, LiverPhase 2
Brazil
14 Nov 2022
Fibrosis, LiverPhase 2
Bulgaria
14 Nov 2022
Fibrosis, LiverPhase 2
Canada
14 Nov 2022
Fibrosis, LiverPhase 2
Spain
14 Nov 2022
Nonalcoholic SteatohepatitisPhase 2
United States
14 Nov 2022
Nonalcoholic SteatohepatitisPhase 2
Japan
14 Nov 2022
Nonalcoholic SteatohepatitisPhase 2
Argentina
14 Nov 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
40
joqyeutsqo(mszpqvlwil) = The histological variables of steatosis (65%, P = 0.001), hepatocellular ballooning (55%, P = 0.002), and lobular inflammation (50%, P = 0.003) were improved in the tofogliflozin group, whereas only hepatocellular ballooning was improved in the glimepiride group (25%, P = 0.025). xonyzcziyb (szeaeksewz )
Positive
27 Jul 2022
Not Applicable
774
(Anemia group)
qbsejmenoh(lnuznxkoni) = mclgmemxrk axefeyqfla (sxcuuhcbwl )
-
01 Jun 2021
(Polycythemia group)
qbsejmenoh(lnuznxkoni) = fgaqimyqwr axefeyqfla (sxcuuhcbwl )
Phase 2
394
Placebo
(Placebo)
chrfgosjpj(dfofjguyia) = eyngentumj cgcfaxqnro (xjpwsizvip, miakspddby - fhnbgzmodd)
-
18 Nov 2020
(RO4998452 5mg)
chrfgosjpj(dfofjguyia) = sxsbqovrsw cgcfaxqnro (xjpwsizvip, tbedqawuew - rxyuxpoehu)
Not Applicable
-
166
omyfqeslsb(akoqmrexst) = ouphovzduj qnhkhiopce (tsyuynlfoo )
-
01 Jun 2020
Not Applicable
12
mmnnnhzbop(ciunrgswij) = gsyqdwhhao eemlswyojr (blmnzifett )
-
01 Jun 2020
(No administration of drugs)
mmnnnhzbop(ciunrgswij) = dxtqiypall eemlswyojr (blmnzifett )
Not Applicable
340
tqgtxfneoa(outypwujwx) = ogoxmrjxcx vvooemfvpn (gzdukekndl )
-
01 Jun 2020
Not Applicable
774
(Quartiles 1-3)
assfghgsav(cbuheytoya) = agbutlawvd pktobzlgva (otqigvngjo )
-
01 Jun 2020
(Quartile 4)
assfghgsav(cbuheytoya) = nafhwhklzn pktobzlgva (otqigvngjo )
Phase 4
67
Tofogliflozin 20 mg + GLP-1 receptor agonist
kazszhfojv(yyanruthbj) = xzffezitwg cofdpixfhx (jbsjqgjsgu )
Positive
01 Nov 2019
Not Applicable
Third line
-
uyfdrohbix(prnsbykmzw) = Adverse events were observed in 27.3% patients in Tofogliflozin 20 mg/day and 29.0% in Glimepiride 0.5 mg/day. None of them were severe. There was one patient experienced hypoglycemia in Glimepiride 0.5 mg/day but none in Tofogliflozin 20 mg/day. vlsqbtfgvm (pkmgjvpcox )
Positive
19 Sep 2019
Not Applicable
-
xnzzscrxzj(qakzxkwpva) = exhetqklfh diexjmevxp (fnmlshffrl )
Positive
01 Jul 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free